TY - JOUR
T1 - Cardiovascular disease in diabetes and the cardiometabolic syndrome
T2 - Focus on minority women
AU - Nicasio, John
AU - El-Atat, Fadi
AU - McFarlane, Samy I.
AU - LaRosa, Judith H.
N1 - Funding Information:
This work is supported by a grant from the National Institutes of Health, K12HD043428, Building Interdisciplinary Research Career in Women’s Health, and by grant support for the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medications (DREAM) study from the Population Health Research Institute at McMaster University (Hamilton, Ontario, Canada).
PY - 2005/6
Y1 - 2005/6
N2 - Diabetes and the cardiometabolic syndrome (CMS) are evolving as global epidemics. In the United States, diabetes affects 20 million people, with 47 million afflicted with the CMS. These disorders have a higher propensity for women, particularly in minority populations with disproportionate increase in cardiovascular disease (CVD) morbidity and mortality. Despite the decline in CVD mortality rates in the general population over the past 35 years parallel to the advances in therapeutic interventions, these rates have increased in women with diabetes. Early preventive measures for CVD risk factor through behavioral and lifestyle modification, smoking cessation, and reduction in psychosocial stressors, as well as pharmacotherapy, are among the currently supported approaches to CVD risk reduction in this high-risk population. In this article, we discuss CVD in people with diabetes and the CMS, with emphasis on minority women, a particularly vulnerable population.
AB - Diabetes and the cardiometabolic syndrome (CMS) are evolving as global epidemics. In the United States, diabetes affects 20 million people, with 47 million afflicted with the CMS. These disorders have a higher propensity for women, particularly in minority populations with disproportionate increase in cardiovascular disease (CVD) morbidity and mortality. Despite the decline in CVD mortality rates in the general population over the past 35 years parallel to the advances in therapeutic interventions, these rates have increased in women with diabetes. Early preventive measures for CVD risk factor through behavioral and lifestyle modification, smoking cessation, and reduction in psychosocial stressors, as well as pharmacotherapy, are among the currently supported approaches to CVD risk reduction in this high-risk population. In this article, we discuss CVD in people with diabetes and the CMS, with emphasis on minority women, a particularly vulnerable population.
UR - http://www.scopus.com/inward/record.url?scp=26844435576&partnerID=8YFLogxK
U2 - 10.1007/s11892-005-0011-6
DO - 10.1007/s11892-005-0011-6
M3 - Review article
C2 - 15929868
AN - SCOPUS:26844435576
SN - 1534-4827
VL - 5
SP - 208
EP - 213
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 3
ER -